Download PDF
Semin Liver Dis 2023; 43(02): 226-233
DOI: 10.1055/a-2104-9034
Review Article

Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease

Jessica K. Bernard
1   Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
,
Corinn Marakovits
1   Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
,
Leah G. Smith
1   Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
,
Heather Francis
1   Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
2   Department of Research, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana
› Author Affiliations Funding This work was supported by the Hickam Endowed Chair, Gastroenterology, Medicine, Indiana University, the Indiana University Health – Indiana University School of Medicine Strategic Research Initiative, the Career Scientist Award (IK6BX005226) and the VA Merit award (1I01BX003031) to H.F. from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development Service, and NIH grants DK108959 and DK119421 (to H.F.). Portions of these studies were supported by resources at the Richard L. Roudebush VA Medical Center, Indianapolis, IN. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.
› Further Information
    Permissions and Reprints


Abstract

Mast cells (MCs) contribute to the pathogenesis of cholestatic liver diseases (primary sclerosing cholangitis [PSC] and primary biliary cholangitis [PBC]). PSC and PBC are immune-mediated, chronic inflammatory diseases, characterized by bile duct inflammation and stricturing, advancing to hepatobiliary cirrhosis. MCs are tissue resident immune cells that may promote hepatic injury, inflammation, and fibrosis formation by either direct or indirect interactions with other innate immune cells (neutrophils, macrophages/Kupffer cells, dendritic cells, natural killer, and innate lymphoid cells). The activation of these innate immune cells, usually through the degranulation of MCs, promotes antigen uptake and presentation to adaptive immune cells, exacerbating liver injury. In conclusion, dysregulation of MC-innate immune cell communications during liver injury and inflammation can lead to chronic liver injury and cancer.

Keywords

mast cells - cholestasis - innate immune cells

Authors' Contributions

J.B. contributed to the drafting and editing the article, figure generation; C.M. contributed to the drafting and editing the article; L.H. contributed to the editing the article and figure generation; H.F. contributed to the funding, editing final draft, and final approval.




Publication History

Accepted Manuscript online:
02 June 2023

Article published online:
05 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77 (04) 1033-1079
    CrossrefPubMedGoogle Scholar
  • 2 Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol 2017; 188 (02) 183-194
    CrossrefPubMedGoogle Scholar
  • 3 Moon TC, Befus AD, Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol 2014; 5: 569
    PubMedGoogle Scholar
  • 4 Owen JA, Punt J, Stratford S. Kuby Immunology. New York: W.H. Freeman & Company; 2013
    PubMedGoogle Scholar
  • 5 Fukuoka Y, Hite MR, Dellinger AL, Schwartz LB. Human skin mast cells express complement factors C3 and C5. J Immunol 2013; 191 (04) 1827-1834
    CrossrefPubMedGoogle Scholar
  • 6 Lipitsä T, Naukkarinen A, Laitala J, Harvima IT. Complement C3 is expressed by mast cells in cutaneous vasculitis and is degraded by chymase. Arch Dermatol Res 2016; 308 (08) 575-584
    CrossrefPubMedGoogle Scholar
  • 7 St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol 2013; 190 (09) 4458-4463
    CrossrefPubMedGoogle Scholar
  • 8 Zhou T, Meadows V, Kundu D. et al. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling. Hepatol Commun 2022; 6 (10) 2715-2731
    CrossrefPubMedGoogle Scholar
  • 9 Meadows V, Kennedy L, Hargrove L. et al. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice. Biochim Biophys Acta Mol Basis Dis 2019; 1865 (12) 165557
    CrossrefPubMedGoogle Scholar
  • 10 Hargrove L, Kennedy L, Demieville J. et al. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient KitW-sh mice. Hepatology 2017; 65 (06) 1991-2004
    CrossrefPubMedGoogle Scholar
  • 11 Jarido V, Kennedy L, Hargrove L. et al. The emerging role of mast cells in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 313 (02) G89-G101
    CrossrefPubMedGoogle Scholar
  • 12 Jones H, Hargrove L, Kennedy L. et al. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. Hepatology 2016; 64 (04) 1202-1216
    CrossrefPubMedGoogle Scholar
  • 13 Kennedy LL, Hargrove LA, Graf AB. et al. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. Lab Invest 2014; 94 (12) 1406-1418
    CrossrefPubMedGoogle Scholar
  • 14 Pham L, Kennedy L, Baiocchi L. et al. Mast cells in liver disease progression: an update on current studies and implications. Hepatology 2022; 75 (01) 213-218
    CrossrefPubMedGoogle Scholar
  • 15 Huang S, Wu H, Luo F. et al. Exploring the role of mast cells in the progression of liver disease. Front Physiol 2022; 13: 964887
    CrossrefPubMedGoogle Scholar
  • 16 Katsoulis-Dimitriou K, Kotrba J, Voss M, Dudeck J, Dudeck A. Mast cell functions linking innate sensing to adaptive immunity. Cells 2020; 9 (12) 2538
    CrossrefPubMedGoogle Scholar
  • 17 Krajewska NM, Fiancette R, Oo YH. Interplay between mast cells and regulatory T cells in immune-mediated cholangiopathies. Int J Mol Sci 2022; 23 (11) 23
    CrossrefPubMedGoogle Scholar
  • 18 McDonald B, McAvoy EF, Lam F. et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J Exp Med 2008; 205 (04) 915-927
    CrossrefPubMedGoogle Scholar
  • 19 Jaeschke H, Farhood A, Fisher MA, Smith CW. Sequestration of neutrophils in the hepatic vasculature during endotoxemia is independent of beta 2 integrins and intercellular adhesion molecule-1. Shock 1996; 6 (05) 351-356
    CrossrefPubMedGoogle Scholar
  • 20 Bajt ML, Farhood A, Jaeschke H. Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am J Physiol Gastrointest Liver Physiol 2001; 281 (05) G1188-G1195
    CrossrefPubMedGoogle Scholar
  • 21 Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm 2012; 949157
    PubMedGoogle Scholar
  • 22 Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol 2017; 17 (04) 248-261
    CrossrefPubMedGoogle Scholar
  • 23 Madjene LC, Danelli L, Dahdah A. et al. Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment. Kidney Int 2020; 97 (03) 516-527
    CrossrefPubMedGoogle Scholar
  • 24 Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 2008; 181 (08) 5598-5605
    CrossrefPubMedGoogle Scholar
  • 25 AhYoung AP, Eckard SC, Gogineni A. et al. Neutrophil serine protease 4 is required for mast cell-dependent vascular leakage. Commun Biol 2020; 3 (01) 687
    CrossrefPubMedGoogle Scholar
  • 26 Pejler G, Alanazi S, Grujic M. et al. Mast cell tryptase potentiates neutrophil extracellular trap formation. J Innate Immun 2022; 14 (05) 433-446
    CrossrefPubMedGoogle Scholar
  • 27 De Giovanni M, Tam H, Valet C, Xu Y, Looney MR, Cyster JG. GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAA. Cell 2022; 185 (05) 815-830.e19
    CrossrefPubMedGoogle Scholar
  • 28 Liu K, Wang FS, Xu R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol 2021; 18 (01) 38-44
    CrossrefPubMedGoogle Scholar
  • 29 Tang J, Yan Z, Feng Q, Yu L, Wang H. The roles of neutrophils in the pathogenesis of liver diseases. Front Immunol 2021; 12: 625472
    CrossrefPubMedGoogle Scholar
  • 30 Minagawa N, Nagata J, Shibao K. et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007; 133 (05) 1592-1602
    CrossrefPubMedGoogle Scholar
  • 31 Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003; 125 (04) 1175-1187
    CrossrefPubMedGoogle Scholar
  • 32 Takeuchi M, Vidigal PT, Guerra MT. et al. Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. Gut 2021; 70 (02) 342-356
    PubMedGoogle Scholar
  • 33 Fabre T, Molina MF, Soucy G. et al. Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis. Sci Immunol 2018; 3 (28) 3
    CrossrefPubMedGoogle Scholar
  • 34 Harty MW, Muratore CS, Papa EF. et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol 2010; 176 (03) 1271-1281
    CrossrefPubMedGoogle Scholar
  • 35 Calvente CJ, Tameda M, Johnson CD. et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019; 129 (10) 4091-4109
    CrossrefPubMedGoogle Scholar
  • 36 Taïeb J, Delarche C, Paradis V. et al. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. J Hepatol 2002; 36 (03) 342-348
    CrossrefPubMedGoogle Scholar
  • 37 Meadows V, Kennedy L, Ekser B. et al. Mast cells regulate ductular reaction and intestinal inflammation in cholestasis through farnesoid X receptor signaling. Hepatology 2021; 74 (05) 2684-2698
    CrossrefPubMedGoogle Scholar
  • 38 Ma YY, Yang MQ, Wang CF, Ding J, Li JY. Inhibiting mast cell degranulation by HO-1 affects dendritic cell maturation in vitro. Inflamm Res 2014; 63 (07) 527-537
    CrossrefPubMedGoogle Scholar
  • 39 Ma YY, Yang MQ, He ZG. et al. Upregulation of heme oxygenase-1 in Kupffer cells blocks mast cell degranulation and inhibits dendritic cell migration in vitro. Mol Med Rep 2017; 15 (06) 3796-3802
    CrossrefPubMedGoogle Scholar
  • 40 Xu JM, Shi GP. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev 2012; 33 (01) 71-108
    CrossrefPubMedGoogle Scholar
  • 41 Bruneau A, Guillot A, Tacke F. Macrophages in cholangiopathies. Curr Opin Gastroenterol 2022; 38 (02) 114-120
    CrossrefPubMedGoogle Scholar
  • 42 Cadamuro M, Girardi N, Gores GJ, Strazzabosco M, Fabris L. The emerging role of macrophages in chronic cholangiopathies featuring biliary fibrosis: an attractive therapeutic target for orphan diseases. Front Med (Lausanne) 2020; 7: 115
    CrossrefPubMedGoogle Scholar
  • 43 Thankam FG, Dilisio MF, Dougherty KA, Dietz NE, Agrawal DK. Triggering receptor expressed on myeloid cells and 5'adenosine monophosphate-activated protein kinase in the inflammatory response: a potential therapeutic target. Expert Rev Clin Immunol 2016; 12 (11) 1239-1249
    CrossrefPubMedGoogle Scholar
  • 44 Labiano I, Agirre-Lizaso A, Olaizola P. et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. J Hepatol 2022; 77 (04) 991-1004
    CrossrefPubMedGoogle Scholar
  • 45 Guicciardi ME, Trussoni CE, Krishnan A. et al. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 2018; 69 (03) 676-686
    CrossrefPubMedGoogle Scholar
  • 46 Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106 (03) 259-262
    CrossrefPubMedGoogle Scholar
  • 47 Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2 (07) 585-589
    CrossrefPubMedGoogle Scholar
  • 48 Caron G, Delneste Y, Roelandts E. et al. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol 2001; 167 (07) 3682-3686
    CrossrefPubMedGoogle Scholar
  • 49 Mazzoni A, Siraganian RP, Leifer CA, Segal DM. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 2006; 177 (06) 3577-3581
    CrossrefPubMedGoogle Scholar
  • 50 Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol 2006; 176 (07) 4102-4112
    CrossrefPubMedGoogle Scholar
  • 51 Shelburne CP, Nakano H, St John AL. et al. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 2009; 6 (04) 331-342
    CrossrefPubMedGoogle Scholar
  • 52 Dawicki W, Jawdat DW, Xu N, Marshall JS. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol 2010; 184 (04) 2116-2123
    CrossrefPubMedGoogle Scholar
  • 53 Reuter S, Dehzad N, Martin H. et al. Mast cells induce migration of dendritic cells in a murine model of acute allergic airway disease. Int Arch Allergy Immunol 2010; 151 (03) 214-222
    CrossrefPubMedGoogle Scholar
  • 54 de Vries VC, Pino-Lagos K, Nowak EC, Bennett KA, Oliva C, Noelle RJ. Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 2011; 35 (04) 550-561
    CrossrefPubMedGoogle Scholar
  • 55 Skokos D, Botros HG, Demeure C. et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003; 170 (06) 3037-3045
    CrossrefPubMedGoogle Scholar
  • 56 Carroll-Portillo A, Cannon JL, te Riet J. et al. Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation. J Cell Biol 2015; 210 (05) 851-864
    CrossrefPubMedGoogle Scholar
  • 57 Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22 (11) 633-640
    CrossrefPubMedGoogle Scholar
  • 58 Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220
    CrossrefPubMedGoogle Scholar
  • 59 Orange JS, Salazar-Mather TP, Opal SM, Biron CA. Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 1997; 71 (12) 9248-9258
    CrossrefPubMedGoogle Scholar
  • 60 Mikulak J, Bruni E, Oriolo F, Di Vito C, Mavilio D. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology. Front Immunol 2019; 10: 946
    CrossrefPubMedGoogle Scholar
  • 61 Male V, Stegmann KA, Easom NJ, Maini MK. Natural killer cells in liver disease. Semin Liver Dis 2017; 37 (03) 198-209
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Portales-Cervantes L, Haidl ID, Lee PW, Marshall JS. Virus-infected human mast cells enhance natural killer cell functions. J Innate Immun 2017; 9 (01) 94-108
    CrossrefPubMedGoogle Scholar
  • 63 Shimoda S, Harada K, Niiro H. et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011; 53 (04) 1270-1281
    CrossrefPubMedGoogle Scholar
  • 64 Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 2006; 176 (04) 2272-2278
    CrossrefPubMedGoogle Scholar
  • 65 Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006; 43 (02) 362-372
    CrossrefPubMedGoogle Scholar
  • 66 Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin Exp Med 2008; 8 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 67 Takeda K, Kojima Y, Ikejima K. et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 2008; 105 (31) 10895-10900
    CrossrefPubMedGoogle Scholar
  • 68 Sakanaka M, Tanaka S, Sugimoto Y, Ichikawa A. Essential role of EP3 subtype in prostaglandin E2-induced adhesion of mouse cultured and peritoneal mast cells to the Arg-Gly-Asp-enriched matrix. Am J Physiol Cell Physiol 2008; 295 (05) C1427-C1433
    CrossrefPubMedGoogle Scholar
  • 69 Ndaw VS, Abebayehu D, Spence AJ. et al. TGF-β1 suppresses IL-33-induced mast cell function. J Immunol 2017; 199 (03) 866-873
    CrossrefPubMedGoogle Scholar
  • 70 Jeong WI, Park O, Suh YG. et al. Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice. Hepatology 2011; 53 (04) 1342-1351
    CrossrefPubMedGoogle Scholar
  • 71 Tao X, Zhang R, Du R. et al. EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model. J Exp Med 2022; 219 (05) 219
    PubMedGoogle Scholar
  • 72 Gasteiger G, Rudensky AY. Interactions between innate and adaptive lymphocytes. Nat Rev Immunol 2014; 14 (09) 631-639
    CrossrefPubMedGoogle Scholar
  • 73 Sun H, Sun C, Tian Z, Xiao W. NK cells in immunotolerant organs. Cell Mol Immunol 2013; 10 (03) 202-212
    CrossrefPubMedGoogle Scholar
  • 74 Hazenberg MD, Spits H. Human innate lymphoid cells. Blood 2014; 124 (05) 700-709
    CrossrefPubMedGoogle Scholar
  • 75 Yokota Y, Mansouri A, Mori S. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999; 397 (6721): 702-706
    CrossrefPubMedGoogle Scholar
  • 76 Spits H. Group 2 innate lymphoid cells show up in the skin. Immunol Cell Biol 2013; 91 (06) 390-392
    CrossrefPubMedGoogle Scholar
  • 77 Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12 (01) 21-27
    CrossrefPubMedGoogle Scholar
  • 78 Symowski C, Voehringer D. Interactions between innate lymphoid cells and cells of the innate and adaptive immune system. Front Immunol 2017; 8: 1422
    CrossrefPubMedGoogle Scholar
  • 79 Liu M, Zhang C. The role of innate lymphoid cells in immune-mediated liver diseases. Front Immunol 2017; 8: 695
    CrossrefPubMedGoogle Scholar
  • 80 Kim CH, Hashimoto-Hill S, Kim M. Migration and tissue tropism of innate lymphoid cells. Trends Immunol 2016; 37 (01) 68-79
    CrossrefPubMedGoogle Scholar
  • 81 McHedlidze T, Waldner M, Zopf S. et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013; 39 (02) 357-371
    CrossrefPubMedGoogle Scholar
  • 82 Li H, Zhan H, Cheng L, Yan S, Wang L, Li Y. Imbalanced distribution of group 2 innate lymphoid cells (ILCs) and ILC precursors in peripheral blood of patients with primary biliary cholangitis. Scand J Immunol 2022; 96 (01) e13166
    CrossrefPubMedGoogle Scholar
  • 83 Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179 (04) 2551-2555
    CrossrefPubMedGoogle Scholar
  • 84 Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998; 161 (09) 4866-4874
    CrossrefPubMedGoogle Scholar
  • 85 Lefrançais E, Duval A, Mirey E. et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 2014; 111 (43) 15502-15507
    CrossrefPubMedGoogle Scholar
  • 86 Liu J, Yang Y, Zheng C. et al. Correlation of interleukin-33/ST2 receptor and liver fibrosis progression in biliary atresia patients. Front Pediatr 2019; 7: 403
    CrossrefPubMedGoogle Scholar
  • 87 van der Ploeg EK, Hermans MAW, van der Velden VHJ, Dik WA, van Daele PLA, Stadhouders R. Increased group 2 innate lymphoid cells in peripheral blood of adults with mastocytosis. J Allergy Clin Immunol 2021; 147 (04) 1490-1496.e2
    CrossrefPubMedGoogle Scholar